You are here: Industry Insights > 20vPnC

News List

Pfizer Explors Coadministration of Its 20-valent Pneumococcal Vaccine With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine americanpharmaceuticalreview
May 28, 2021
Pfizer announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate ...
Pfizer’s pneumococcal disease vaccine scores FDA priority review pharmatimes
December 10, 2020
The US Food and Drug Administration (FDA) has granted Pfizer’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate a priority review for the prevention of pneumococcal disease.
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older drugs
April 18, 2019
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older